C12N 2830/00
Vector systems having a special element relevant for transcription
C12N2830/00 (Vector systems having a special element relevant for transcription) appears on 3,438 US grants and 6,033 published applications in this corpus.
Search patents in C12N- Granted patents
- 3,438
- Published applications
- 6,033
- Assignees
- 2,183
- Inventors
- 10,956
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1986 | 1 | 0 |
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 2 | 0 |
| 1990 | 2 | 0 |
| 1991 | 2 | 0 |
| 1992 | 8 | 0 |
| 1993 | 16 | 0 |
| 1994 | 19 | 0 |
| 1995 | 17 | 0 |
| 1996 | 46 | 0 |
| 1997 | 90 | 0 |
| 1998 | 126 | 0 |
| 1999 | 119 | 0 |
| 2000 | 122 | 0 |
| 2001 | 132 | 36 |
| 2002 | 125 | 197 |
| 2003 | 108 | 316 |
| 2004 | 65 | 249 |
| 2005 | 82 | 243 |
| 2006 | 98 | 238 |
| 2007 | 123 | 175 |
| 2008 | 76 | 168 |
| 2009 | 90 | 153 |
| 2010 | 102 | 191 |
| 2011 | 82 | 152 |
| 2012 | 87 | 132 |
| 2013 | 83 | 100 |
| 2014 | 88 | 127 |
| 2015 | 102 | 161 |
| 2016 | 98 | 151 |
| 2017 | 111 | 176 |
| 2018 | 108 | 204 |
| 2019 | 109 | 206 |
| 2020 | 135 | 244 |
| 2021 | 121 | 315 |
| 2022 | 135 | 352 |
| 2023 | 143 | 364 |
| 2024 | 134 | 425 |
| 2025 | 182 | 495 |
| 2026 | 148 | 463 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2830/008Cell type or tissue specific enhancer/promoter combinationIndexing code1,375
- C12N 2830/001Controllable enhancer/promoter combinationIndexing code1,006
- C12N 2830/80From vertebratesIndexing code768
- C12N 2830/42Being an intron or intervening sequence for splicing and/or stability of rnaIndexing code533
- C12N 2830/15Chimeric enhancer/promoter combinationIndexing code401
- C12N 2830/60From virusesIndexing code384
- C12N 2830/50Regulating rna stability, not being an intronIndexing code321
- C12N 2830/48Regulating transport or export of rnaIndexing code250
All 22 subgroupsShow fewer
- C12N 2830/30Being an enhancer not forming part of the promoter regionIndexing code176
- C12N 2830/55From bacteriaIndexing code153
- C12N 2830/20Transcription of more than one cistronIndexing code124
- C12N 2830/46Elements influencing chromatin structureIndexing code92
- C12N 2830/40Being an insulatorIndexing code85
- C12N 2830/38Being a stufferIndexing code72
- C12N 2830/70From fungiIndexing code69
- C12N 2830/007Cell cycle specific enhancer/promoter combinationIndexing code53
- C12N 2830/36Being a transcription termination elementIndexing code47
- C12N 2830/75From invertebratesIndexing code47
- C12N 2830/34Being a transcription initiation elementIndexing code44
- C12N 2830/32Being an silencer not forming part of the promoter regionIndexing code32
- C12N 2830/52Encoding ribozyme for self-inactivationIndexing code13
- C12N 2830/65From plantsIndexing code7
Recent patents
- Compositions useful for treatment of Charcot-Marie-Tooth disease6 Oct 2026US 12,753,419 B2The Trustees of the University of Pennsylvania
- Riboswitch modulated gene therapy for retinal diseases29 Sep 2026US 12,747,441 B2The Medical College of Wisconsin, Inc.
- Interneuron-specific therapeutics for normalizing neuronal cell excitability and treating Dravet syndrome29 Sep 2026US 12,747,452 B2New York University
- Gene-therapy vectors for treating cardiomyopathy29 Sep 2026US 12,747,453 B2
- Genetically engineered phagocytes, and related compositions, vectors, methods and systems22 Sep 2026US 12,741,025 B2The Regents of the University of California
- Recombinant adeno-associated viral vectors for multipartite gene delivery and stargardt disease treatment8 Oct 2026US 2026/0306667 A1Abeona Therapeutics Inc.
- Methods of treating neurodegenerative disorders8 Oct 2026US 2026/0306669 A1
- Targeting gpatch8 for treating sf3b1-mutant cancers8 Oct 2026US 2026/0306672 A1Fred Hutchinson Cancer Center
- Modified adeno-associated virus vector and use thereof in treating neurological diseases8 Oct 2026US 2026/0306673 A1Genecombio Ltd.
- Epigenetic repression protein therapy for rasopathies8 Oct 2026US 2026/0306675 A1Battelle Memorial Institute
Most cited
By later US patents
- Ransgenic non-human animals for producing heterologous antibodies1,941US 5,545,806 AGenPharm International, Inc. · 1996
- Transgenic non-human animals capable of producing heterologous antibodies of various isotypes1,748US 5,569,825 AGenPharm International, Inc. · 1996
- Transgenic non-human animals capable of producing heterologous antibodies1,680US 5,633,425 AGenPharm International, Inc. · 1997
- Transgenic non-human animals for producing heterologous antibodies1,604US 5,625,126 AGenPharm International, Inc. · 1997
- Transgenic non-human animals capable of producing heterologous antibodies950US 5,770,429 AGenPharm International, Inc. · 1998